943 Mrv0541 02231215072 d 15 16 0 0 1 0 999 V2000型3.7465 -0.7106 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 3.6409 -2.9164 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 1.6500 0.5994 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 3.0791 0.5994 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 2.3645 1.8369 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 3.0791 3.0744 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 3.0791 -0.2256 0.0000 C 0 0 1 0 0 0 0 0 0 0 0 0 2.4115 -0.7106 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.6665 -1.4952 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 3.4916 -1.4952 0.0000 C 0 0 1 0 0 0 0 0 0 0 0 0 3.9764 -2.1627 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 3.7935 1.0119 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.3645 1.0119 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 3.7935 1.8369 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 3.0791 2.2494 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1 7 1 10 0 0 0 0 1 1 0 0 0 0 2 11 1 0 0 0 0 3 13 2 0 0 0 0 7 4 1 6 0 0 0 4 12 1 0 0 0 0 4 13 13 1 0 0 0 0 5 1 0 0 0 0 5 15 2 0 0 0 0 6 15 1 0 0 0 0 7 8 1 0 0 0 0 8 9 1 0 0 0 0 9 10 1 0 0 0 0 10 11 1 6 0 0 0 12 14 2 0 0 0 0 14 15 1 0 0 0 0 M >结束
DB00943 >
drugbank >
NC1 =数控(= O) N (C = C1) [C@H] 1 cc (C@@H) (CO) O1 >
InChI = 1 s / C9H13N3O3 c10-7-3-4-12(9(14) 11-7) 8-2-1-6 - 8第5 - 13 ()/ h3-4, 6、8、13 h, 1 - 2, 5 H2 (H2, 10、11、14) / t6 -, 8 + / mo / s1 >
WREGKURFCTUGRC-POYBYMJQSA-N >
C9H13N3O3 >
211.2178 >
211.095691297 >
5 >
28日>
0.002977633399039742 >
20.92289888220313 >
1 >
2 >
0 >
0 >
4-amino-1 - [(2 r, 5 s) 5 -(羟甲基)oxolan-2-yl] 1, 2-dihydropyrimidin-2-one >
-1.29 >
-1.1882264563333331 >
-1.48 >
0 >
0 >
2 >
0 >
19.21725074537269 >
14.673289182412136 >
4.475169413992644 >
88.15 >
52.24020000000001 >
2 >
1 >
7.05 e + 00 g / l >
生物素>
0 >
DB00943 >
APRD00562 >
批准;临床实验的>
Zalcitabine >
2 ',3 '双脱氧胞苷;4-amino-1 - [(2 r, 5 s) 5 -(羟甲基)tetrahydrofuran-2-yl] pyrimidin-2 (1 h)——;监护系统;DDCYD;双脱氧胞苷;Zalcitabine >
Hivid;Hivid Tab 0.375毫克;$ $ $ $ Hivid Tab 0.75毫克